Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Tolerx
company
About
Tolerx develops novel therapies that modulate T-cell activities to treat patients with autoimmune diseases, diabetes and cancer.
- 51 - 100
Highlights
Details
- Last Funding Type
- Series D
- Last Funding Money Raised
- $61M
- Industries
- Biotechnology,Health Care,Medical
- Founded date
- Jan 1, 2000
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Tolerx, Inc. develops novel therapies focusing on modulating T-cell activities for treating autoimmune diseases, diabetes, and cancer. The company's products include otelixizumab, a targeted T-cell immunomodulator for treating type 1 diabetes; MTRX1011A, an anti-CD4 antibody for treating autoimmune indications; and TRX518 and TRX385, pre-clinical candidates that focuses on optimizing immune responses for treating cancer and chronic viral diseases. Tolerx, Inc., formerly known as TolerRx, Inc., was founded in 2000 and is based in Cambridge, Massachusetts.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$92M
Tolerx has raised a total of
$92M
in funding over 2 rounds. Their latest funding was raised on
Oct 21, 2006 from a Series D round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Oct 21, 2006 | Series D | $61M | 1 |
|
— | Detail |
| Mar 29, 2005 | Series D | $31M | 1 |
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
2
1
Tolerx is funded by 1 investors.
Bear Stearns Health Innoventures L.P
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Series D |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
